Premature Ejaculation Treatment Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The premature ejaculation treatment market size has grown strongly in recent years. It will grow from $3.88 billion in 2024 to $4.27 billion in 2025 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to increasing prevalence of premature ejaculation, growing awareness and reduced stigma, physician and patient education, changing societal attitudes toward sexual health, expansion of telemedicine services, pharmaceutical industry initiatives.

The premature ejaculation treatment market size is expected to see strong growth in the next few years. It will grow to $6.16 billion in 2029 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to continued focus on sexual health, individualized treatment approaches, global efforts to address sexual dysfunction, online health platforms and apps, increased openness in healthcare discussions. Major trends in the forecast period include rise in behavioral and psychosexual therapies, development of novel topical therapies, advancements in pharmacological treatments, integration of telemedicine and online platforms, focus on patient education and counseling, research on novel mechanisms of action.

The increasing prevalence of sexual disorders is expected to propel the growth of the premature ejaculation treatment market going forward. Sexual disorders, or dysfunctions, refer to difficulties that individuals experience during any phase of regular intimate activity. Premature ejaculation, a common sexual disorder among men, requires targeted treatments such as medications or therapeutic approaches to manage and control the condition. For instance, a survey conducted in July 2022 by Click2Pharmacy, a UK-based provider of local prescription treatment services, revealed that around 58.2% of men in the UK experienced erectile dysfunction. Notably, three in four men aged 25 to 34 reported experiencing erectile dysfunction in 2022. The growing prevalence of such sexual disorders is driving the demand for premature ejaculation treatment, fueling the market's growth.

The rise in awareness about sexual health is expected to further fuel the growth of the premature ejaculation treatment market. Sexual health encompasses holistic well-being, including the physical, emotional, cognitive, and social dimensions of one's sexuality. Increased awareness about sexual health is crucial for effective premature ejaculation treatment, fostering understanding, communication, and informed decision-making. In October 2023, the UK Health Security Agency, a UK-based government agency, reported a notable increase in consultations at sexual health services (SHSs), reaching a total of 4,394,404 in 2022. This represented an 8.2% rise from the previous year, with the count standing at 4,059,608 in 2021. Therefore, the growing awareness about sexual health is playing a significant role in propelling the growth of the premature ejaculation treatment market.

Key companies in the premature ejaculation treatment market are focusing on developing new solutions, such as delay sprays, to drive revenues. Delay sprays are specially formulated products applied to the penis before sexual activity to help men last longer during intercourse. They work by temporarily dulling penis nerves, reducing penis sensitivity, and delaying ejaculation. For instance, in August 2023, Maude, a US-based sexual wellness company, introduced Stay, a delay spray explicitly designed to address premature ejaculation. This product contains 10% lidocaine, a fast-evaporating local anesthetic that reduces sensitivity in the male genital region. Stay is compatible with both latex and polyisoprene condoms, various lubricants, and devices. It is vegan-friendly, fragrance-free, and free from sulfates, silicones, and parabens.

In September 2022, Advanced MedTech Holdings (AMTH), a Singapore-based medical technology manufacturing company, acquired Shenzhen Wikkon Medical Apparatus Co. Ltd. for an undisclosed amount. This acquisition enhances AMTH's footprint in China and broadens its global urology platform. By combining WIKKON’s innovative technologies with AMTH’s extensive resources, the acquisition positions the company to better serve both domestic and international markets. Shenzhen Wikkon Medical Apparatus Co. Ltd. is a China-based medical device company specializing in urology and shock wave therapy devices, as well as treatments for premature ejaculation.

Major companies operating in the premature ejaculation treatment market report are Pfizer Inc., Johnson & Johnson, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Menarini Group, Lupin Limited., Amneal Pharmaceuticals Inc., Mankind Pharma Ltd., Cipla Limited, Alembic Pharmaceuticals Limited, Torrent Pharmaceuticals Ltd., ANI Pharmaceuticals Inc., Sagent Pharmaceuticals Inc., Vivus Inc., Absorption Pharmaceuticals LLC, Innovus Pharmaceuticals Inc., Sunrise Pharmaceuticals Inc., Solco Healthcare US LLC, Apricus Biosciences Inc., Regent Pacific Group Limited, Endurance RP Ltd.

North America was the largest region in the premature ejaculation treatment market in 2024, and is expected to be the fastest-growing region in the forecast period. The regions covered in the premature ejaculation treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the premature ejaculation treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The premature ejaculation treatment market includes revenues earned by entities by providing services such as psychological therapy, cognitive-behavioral therapy and behavioral therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The premature ejaculation treatment market consists of sales of medications, inhibitors and drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Premature ejaculation treatment involves the use of medication or therapy to address and manage the symptoms of premature ejaculation. This type of treatment encompasses the application of medicines or therapeutic interventions to tackle and alleviate premature ejaculation.

The main types of premature ejaculation treatments include antidepressants (SSRIs), phosphodiesterase-5 inhibitors, topical anesthetics, analgesics, and other therapeutic options. Selective serotonin reuptake inhibitors (SSRIs) are a class of antidepressant medications commonly used for treating depression. These treatments can be administered orally or topically and may be obtained through retail or direct-to-consumer channels. Various applications for premature ejaculation treatments include hospitals, retail pharmacies, online pharmacies, and other healthcare settings.

The premature ejaculation treatment market research report is one of a series of new reports that provides premature ejaculation treatment market statistics, including premature ejaculation treatment industry global market size, regional shares, competitors with a premature ejaculation treatment market share, detailed premature ejaculation treatment market segments, market trends and opportunities, and any further data you may need to thrive in the premature ejaculation treatment industry. This premature ejaculation treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.